MFDS
- Marketing authorisation holder: SYNDAX
- Status: likely_approved
🇰🇷 Revuforj in South Korea
Revuforj (REVUMENIB) regulatory status in South Korea.
Marketing authorisation
Revuforj in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in South Korea
Frequently asked questions
Is Revuforj approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Revuforj in South Korea?
SYNDAX holds the South Korean marketing authorisation.